Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 903

1.

Eicosapentaenoic Acid and Prevalence of Cardiovascular Disease in Hemodialysis Patients.

Honda T, Kishi S, Furukawa E, Ambe H, Kurata Y, Ichikawa M, Aoe M, Ohara K, Furuse S, Saito K, Nishio K, Masaki K, Kano T, Mise N.

Ther Apher Dial. 2018 Jul 10. doi: 10.1111/1744-9987.12677. [Epub ahead of print]

PMID:
29987872
2.

A case of ALK-rearranged non-small cell lung cancer that responded to ceritinib after development of resistance to alectinib.

Makuuchi Y, Hayashi H, Haratani K, Tanizaki J, Tanaka K, Takeda M, Sakai K, Shimizu S, Ito A, Nishio K, Nakagawa K.

Oncotarget. 2018 May 1;9(33):23315-23319. doi: 10.18632/oncotarget.25143. eCollection 2018 May 1.

3.

Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.

Takeda M, Sakai K, Hayashi H, Tanaka K, Tanizaki J, Takahama T, Haratani K, Nishio K, Nakagawa K.

Oncotarget. 2018 Apr 20;9(30):21132-21140. doi: 10.18632/oncotarget.24958. eCollection 2018 Apr 20.

4.

Effects of Antifreeze Protein Supplementation on the Development of Porcine Morulae Stored at Hypothermic Temperatures.

Nguyen TV, Tanihara F, Hirata M, Hirano T, Nishio K, Kim Do LT, Nguyen TV, Nii M, Otoi T.

Cryo Letters. 2018 Mar/Apr;39(2):131-136.

PMID:
29734422
5.

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.

Sakai H, Tsurutani J, Iwasa T, Komoike Y, Sakai K, Nishio K, Nakagawa K.

Breast Cancer. 2018 Apr 26. doi: 10.1007/s12282-018-0861-9. [Epub ahead of print]

PMID:
29700710
6.

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.

Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T.

Breast. 2018 Aug;40:67-75. doi: 10.1016/j.breast.2018.04.010. Epub 2018 Apr 23.

PMID:
29698927
7.

Thioether Macrocyclic Peptides Selected against TET1 Compact Catalytic Domain Inhibit TET1 Catalytic Activity.

Nishio K, Belle R, Katoh T, Kawamura A, Sengoku T, Hanada K, Ohsawa N, Shirouzu M, Yokoyama S, Suga H.

Chembiochem. 2018 May 4;19(9):979-985. doi: 10.1002/cbic.201800047. Epub 2018 Apr 17.

PMID:
29665240
8.

Genital mucosal melanoma with somatic SF3B1 R625C mutation.

Oiso N, Sakai K, Yanagihara S, Nishio K, Kawada A.

Eur J Dermatol. 2018 Apr 6. doi: 10.1684/ejd.2018.3281. [Epub ahead of print] No abstract available.

PMID:
29624176
9.

Von Willebrand Factor Aggravates Hepatic Ischemia-Reperfusion Injury by Promoting Neutrophil Recruitment in Mice.

Urisono Y, Sakata A, Matsui H, Kasuda S, Ono S, Yoshimoto K, Nishio K, Sho M, Akiyama M, Miyata T, Okuchi K, Nishimura S, Sugimoto M.

Thromb Haemost. 2018 Apr;118(4):700-708. doi: 10.1055/s-0038-1636529. Epub 2018 Apr 4.

PMID:
29618155
10.

B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.

Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K.

Clin Cancer Res. 2018 Jun 1;24(11):2653-2664. doi: 10.1158/1078-0432.CCR-17-2852. Epub 2018 Mar 12.

PMID:
29530936
11.

Rapid Enzyme-linked Immunosorbent Assays for Diagnosis of Diabetes in a Compact Disc-shaped Microfluidic Device.

Furutani S, Nishio K, Naruishi N, Akazawa-Ogawa Y, Hagihara Y, Yoshida Y, Nagai H.

Anal Sci. 2018;34(3):379-382. doi: 10.2116/analsci.34.379.

12.

Wavelength division multiplexer based on cavity-resonator-integrated guided-mode resonance filters for a compact multi-wavelength light source.

Inoue J, Tsuji A, Kintaka K, Nishio K, Ura S.

Opt Express. 2018 Feb 5;26(3):2212-2219. doi: 10.1364/OE.26.002212.

PMID:
29401761
13.

Ultrathin silicon oxynitride layer on GaN for dangling-bond-free GaN/insulator interface.

Nishio K, Yayama T, Miyazaki T, Taoka N, Shimizu M.

Sci Rep. 2018 Jan 23;8(1):1391. doi: 10.1038/s41598-018-19283-4.

14.

Mycobacterium triplex pulmonary disease with acquired macrolide resistance in immunocompetent patients.

Matsuda S, Suzuki S, Morimoto K, Aono A, Nishio K, Asakura T, Sasaki Y, Namkoong H, Nishimura T, Ogata H, Hasegawa N, Kurashima A, Ishii M, Tatsumi K, Mitarai S, Goto H.

Clin Microbiol Infect. 2018 Jun;24(6):671-672. doi: 10.1016/j.cmi.2017.12.018. Epub 2018 Jan 5. No abstract available.

PMID:
29309938
15.

Role of Multichance Fission in the Description of Fission-Fragment Mass Distributions at High Energies.

Hirose K, Nishio K, Tanaka S, Léguillon R, Makii H, Nishinaka I, Orlandi R, Tsukada K, Smallcombe J, Vermeulen MJ, Chiba S, Aritomo Y, Ohtsuki T, Nakano K, Araki S, Watanabe Y, Tatsuzawa R, Takaki N, Tamura N, Goto S, Tsekhanovich I, Andreyev AN.

Phys Rev Lett. 2017 Dec 1;119(22):222501. doi: 10.1103/PhysRevLett.119.222501. Epub 2017 Nov 27.

PMID:
29286806
16.

Immunohistological Localization of Peroxisome Proliferator-Activated Receptor α and γ in Human Sebaceous Glands.

Furue M, Takemura M, Nishio K, Sato Y, Nagata S, Kan N, Suenaga A, Furue K, Yoshida M, Konishi S, Tsuji G.

Fukuoka Igaku Zasshi. 2016 Nov;107(11):199-203.

PMID:
29227070
17.

Effects of voltage strength during electroporation on the development and quality of in vitro-produced porcine embryos.

Nishio K, Tanihara F, Nguyen TV, Kunihara T, Nii M, Hirata M, Takemoto T, Otoi T.

Reprod Domest Anim. 2018 Apr;53(2):313-318. doi: 10.1111/rda.13106. Epub 2017 Nov 14.

PMID:
29135047
18.

[Clinical Application of NGS-Based Clinical Sequencing].

Nishio K, Sakai K.

Gan To Kagaku Ryoho. 2017 Oct;44(10):813-816. Review. Japanese.

PMID:
29066670
19.

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.

Murakami Y, Sonoda K, Abe H, Watari K, Kusakabe D, Azuma K, Kawahara A, Akiba J, Oneyama C, Pachter JA, Sakai K, Nishio K, Kuwano M, Ono M.

Oncotarget. 2017 Aug 7;8(41):70736-70751. doi: 10.18632/oncotarget.19982. eCollection 2017 Sep 19.

20.

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).

Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K.

BMC Cancer. 2017 Oct 6;17(1):674. doi: 10.1186/s12885-017-3664-z.

21.

Characteristics of patients with increasing COPD assessment test scores within 3 years.

Irie H, Chubachi S, Sato M, Tsutsumi A, Nakachi I, Miyao N, Nishio K, Nakamura H, Asano K, Betsuyaku T.

Respir Med. 2017 Oct;131:101-108. doi: 10.1016/j.rmed.2017.08.012. Epub 2017 Aug 14.

PMID:
28947014
22.

Lymph node metastatic melanoma from ungual melanoma: Identification of somatic mutations in KIT and LZTR1.

Oiso N, Sakai K, Narita T, Yanagihara S, Nishio K, Kawada A.

J Dermatol. 2018 Jan;45(1):e5-e6. doi: 10.1111/1346-8138.14071. Epub 2017 Sep 25. No abstract available.

PMID:
28944487
23.

Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer.

Matsuoka H, Makimura C, Koyama A, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.

Biomed Rep. 2017 Oct;7(4):380-384. doi: 10.3892/br.2017.963. Epub 2017 Aug 8.

24.

Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.

Nishio K, Kimura K, Amano R, Nakata B, Yamazoe S, Ohira G, Miura K, Kametani N, Tanaka H, Muguruma K, Hirakawa K, Ohira M.

World J Gastroenterol. 2017 Aug 21;23(31):5764-5772. doi: 10.3748/wjg.v23.i31.5764.

25.

Ascorbic acid prevents zinc oxide nanoparticle-induced intracellular oxidative stress and inflammatory responses.

Fukui H, Iwahashi H, Nishio K, Hagihara Y, Yoshida Y, Horie M.

Toxicol Ind Health. 2017 Sep;33(9):687-695. doi: 10.1177/0748233717707361. Epub 2017 Aug 31.

PMID:
28854869
26.

Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation.

Udo E, Furusato B, Sakai K, Prentice LM, Tanaka T, Kitamura Y, Tsuchiya T, Yamasaki N, Nagayasu T, Nishio K, Fukuoka J.

Diagn Pathol. 2017 Aug 22;12(1):62. doi: 10.1186/s13000-017-0651-2.

27.

hsa-miR-346 is a potential serum biomarker of Mycobacterium avium complex pulmonary disease activity.

Nishimura T, Tamizu E, Uno S, Uwamino Y, Fujiwara H, Nishio K, Nakano Y, Shiono H, Namkoong H, Hoshino Y, Iwata S, Hasegawa N.

J Infect Chemother. 2017 Oct;23(10):703-708. doi: 10.1016/j.jiac.2017.07.015. Epub 2017 Aug 19.

PMID:
28827075
28.

Functional expression of BMP7 receptors in oral epithelial cells. Interleukin-17F production in response to BMP7.

Nishio K, Ozawa Y, Ito H, Kifune T, Narita T, Iinuma T, Gionhaku N, Asano M.

J Recept Signal Transduct Res. 2017 Oct;37(5):515-521. doi: 10.1080/10799893.2017.1360352.

PMID:
28812969
29.

Three-dimensional imaging of distribution of refractive index by parallel phase-shifting digital holography using Abel inversion.

Fukuda T, Wang Y, Xia P, Awatsuji Y, Kakue T, Nishio K, Matoba O.

Opt Express. 2017 Jul 24;25(15):18066-18071. doi: 10.1364/OE.25.018066.

PMID:
28789296
30.

Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.

Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, Serizawa K, Rai S, Morita Y, Hanamoto H, Tsubaki K, Nishio K, Matsumura I.

Int J Hematol. 2017 Nov;106(5):691-703. doi: 10.1007/s12185-017-2302-5. Epub 2017 Aug 5.

PMID:
28780601
31.

Nuclear fission: a review of experimental advances and phenomenology.

Andreyev AN, Nishio K, Schmidt KH.

Rep Prog Phys. 2018 Jan;81(1):016301. doi: 10.1088/1361-6633/aa82eb.

PMID:
28753131
32.

Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.

Sakai K, Ukita M, Schmidt J, Wu L, De Velasco MA, Roter A, Jevons L, Nishio K, Mandai M.

Cancer Lett. 2017 Oct 1;405:22-28. doi: 10.1016/j.canlet.2017.07.013. Epub 2017 Jul 19.

33.

Interferon related pericarditis: Review.

Nishio K, Arase T, Tada H, Tachibana H.

World J Cardiol. 2017 Jun 26;9(6):553-557. doi: 10.4330/wjc.v9.i6.553.

34.

Inhibitory effects of local anesthetics on the proteasome and their biological actions.

Bahrudin U, Unno M, Nishio K, Kita A, Li P, Kato M, Inoue M, Tsujitani S, Murakami T, Sugiyama R, Saeki Y, Obara Y, Tanaka K, Yamaguchi H, Sakane I, Kawata Y, Itoh T, Ninomiya H, Hisatome I, Morimoto Y.

Sci Rep. 2017 Jul 11;7(1):5079. doi: 10.1038/s41598-017-04652-2.

35.

DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.

Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J.

Int J Cancer. 2017 Oct 15;141(8):1682-1689. doi: 10.1002/ijc.30870. Epub 2017 Jul 12.

PMID:
28677116
36.

A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.

Hayashi H, Chiba Y, Sakai K, Fujita T, Yoshioka H, Sakai D, Kitagawa C, Naito T, Takeda K, Okamoto I, Mitsudomi T, Kawakami Y, Nishio K, Nakamura S, Yamamoto N, Nakagawa K.

Clin Lung Cancer. 2017 Nov;18(6):719-723. doi: 10.1016/j.cllc.2017.05.012. Epub 2017 May 25.

PMID:
28623122
37.
38.

Crystallographic and electronic properties of AlCrN films that absorb visible light.

Tatemizo N, Imada S, Miura Y, Nishio K, Isshiki T.

AIP Adv. 2017 May 10;7(5):055306. doi: 10.1063/1.4983491. eCollection 2017 May.

39.

Analysis of Aprotinin, a Protease Inhibitor, Action on the Trafficking of Epithelial Na+ Channels (ENaC) in Renal Epithelial Cells Using a Mathematical Model.

Sasamoto K, Marunaka R, Niisato N, Sun H, Taruno A, Pezzotti G, Yamamoto T, Kanamura N, Zhu W, Nishio K, Inui T, Eaton DC, Marunaka Y.

Cell Physiol Biochem. 2017;41(5):1865-1880. doi: 10.1159/000471934. Epub 2017 Apr 4.

40.

Incidence of carnitine deficiency in patients with cancer pain: A pilot study.

Sakai K, Matsuoka H, Ohtake Y, Makimura C, Izumi H, Fujita Y, Otsuka M, Tsurutani J, Nishio K, Nakagawa K, Koyama A.

Mol Clin Oncol. 2017 Mar;6(3):331-333. doi: 10.3892/mco.2017.1159. Epub 2017 Feb 7.

41.

Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.

Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M, Kudo M, Nishio K.

Int J Oncol. 2017 Jun;50(6):2049-2058. doi: 10.3892/ijo.2017.3961. Epub 2017 Apr 18.

PMID:
28440469
42.

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.

Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.

BMC Cancer. 2017 Apr 19;17(1):281. doi: 10.1186/s12885-017-3263-z. No abstract available.

43.

Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.

Tsubaki M, Takeda T, Kino T, Sakai K, Itoh T, Imano M, Nakayama T, Nishio K, Satou T, Nishida S.

Oncotarget. 2017 Jun 13;8(24):38717-38730. doi: 10.18632/oncotarget.16314.

44.

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.

Ann Oncol. 2017 Jul 1;28(7):1532-1539. doi: 10.1093/annonc/mdx183.

PMID:
28407039
45.

Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.

Matsuoka H, Kaneda H, Sakai K, Koyama A, Nishio K, Nakagawa K.

Clin Lung Cancer. 2017 Jan;18(1):e85-e87. doi: 10.1016/j.cllc.2016.08.004. Epub 2016 Oct 4. No abstract available.

PMID:
28341110
46.

Frequency and role of NKp46 and NKG2A in hepatitis B virus infection.

Yoshioka T, Tatsumi T, Miyagi T, Mukai K, Nishio K, Nishio A, Yokoyama Y, Suda T, Kegasawa T, Shigekawa M, Hikita H, Sakamori R, Takehara T.

PLoS One. 2017 Mar 22;12(3):e0174103. doi: 10.1371/journal.pone.0174103. eCollection 2017.

47.

The H3K27 demethylase, Utx, regulates adipogenesis in a differentiation stage-dependent manner.

Ota K, Tong KI, Goto K, Tomida S, Komuro A, Wang Z, Nishio K, Okada H.

PLoS One. 2017 Mar 20;12(3):e0173713. doi: 10.1371/journal.pone.0173713. eCollection 2017. Erratum in: PLoS One. 2017 Apr 19;12 (4):e0176424.

48.

Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine.

Matsuoka H, Yoshiuchi K, Koyama A, Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.

Int J Behav Med. 2017 Aug;24(4):535-541. doi: 10.1007/s12529-017-9644-5.

49.

Sensitivity of the meiotic stage to hyperthermia during in vitro maturation of porcine oocytes.

Nishio K, Yamazaki M, Taniguchi M, Besshi K, Morita F, Kunihara T, Tanihara F, Takemoto T, Otoi T.

Acta Vet Hung. 2017 Mar;65(1):115-123. doi: 10.1556/004.2017.012.

PMID:
28244334
50.

Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.

Iwama E, Sakai K, Azuma K, Harada T, Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.

Ann Oncol. 2017 Jan 1;28(1):136-141. doi: 10.1093/annonc/mdw531.

PMID:
28177428

Supplemental Content

Loading ...
Support Center